The Italian biotech Externautics, participated by the Italian Funds Biofund and Value Italy SGR S.p.A. and the biotech company PRIMM, and incubated at TLS Foundation’s Medicine Research Centre in Siena, recently out-licensed an important oncological biomarker to a large pharmaceutical company. This license agreement further validates the strength of Externautics’s platform in the generation of high quality lead drug candidates.
According to Mr. Aleardo Furlani, CEO of Externautics: "promising negotiations for the out-licensing of other biomarkers in Externautics pipeline are now ongoing with other big Pharma and research laboratories”.
EXTERNAUTICS is an innovative biotech company established in 2007 to exploit the unique possibilities offered by the Reverse Proteomic YOMICS® Platform toward the identification and development of novel diagnostic and therapeutic markers for Oncology applications.
The company is based in Siena, Italy, in the stimulating Bio-Incubator of Toscana Life Sciences, where it benefits from the proximity of an important scientific community in which academic and industrial research meet and help the advancement of small and young companies like Externautics. The company was founded by a team of scientists and entrepreneurs with strong experience in the management of biotech companies and industrial R&D. The company is partnering with major biotech investment funds.
Investors and Partners
Presently the shareholders are: PRIMM Srl, a biotech company based in Milan, MPS Venture SGR, a venture capital firm based in Florence and Biofund, an investment fund based in Siena, Italy
Primm is a biotech company established in 1989, specialized in the manufacturing and sale of Custom Services for the international scientific community. Primm is also engaged in Research and Development activities in the area of Oncology and Neurodegeneration, exploiting the internal know how developed over years of management of custom services. Primm is based in Milan, and its main operational site is at the San Raffaele Science Park. Additional manufacturing sites are based in Treviso and Naples.
About MPS Venture SGR
MPS VENTURE SGR SpA, a member of the Monte dei Paschi Banking Group, was established in September 2001 with the purpose of managing closed-end investment funds in Italy. Since its founding, MPS Venture SGR has invested in over 35 acquisitions. Leader in number of funds managed, transactions in portfolio, divestments and reimbursements, MPS Venture SGR currently manages 6 closed-end funds worth some 400 Million Euro.
BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi, Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.